RESUMEN
This brief provides data for policy changes on the intersection of polluting industrial facilities, marginalized communities, and the dearth of air-quality monitors in those communities of South Chicago. The allocation of air-quality monitors is determined by the Illinois Environmental Protection Agency (IEPA). Our data demonstrate that the air quality and subsequent health of Chicago's marginalized communities are chronically threatened by the expansion of polluting industries coupled with inadequate air-quality monitoring. The methods of data analysis presented here can be similarly applied to analyze air-quality disparities in communities beyond Chicago, including those that have been victims of environmental injustice stemming from redlining. Such data can be used to support Environmental Justice (EJ) advocacy and goals by informing remedial actions and policies of regulatory bodies, such as the IEPA, to reduce disproportionate air-quality burdens through increased monitoring. The generated maps may be used to direct plans for assessing and mitigating the effects of air pollution on human health.
Asunto(s)
Contaminación del Aire , Justicia Ambiental , Chicago , Monitoreo del Ambiente/métodos , HumanosRESUMEN
Low-grade inflammation is often an underlying cause of several chronic diseases such as asthma, obesity, cardiovascular disease, and type 2 diabetes mellitus (T2DM). Defining the mediators of such chronic low-grade inflammation often appears dependent on which disease is being investigated. However, downstream systemic inflammatory cytokine responses in these diseases often overlap, noting there is no doubt more than one factor at play to heighten the inflammatory response. Furthermore, it is increasingly believed that diet and an altered gut microbiota may play an important role in the pathology of such diverse diseases. More specifically, the inflammatory mediator endotoxin, which is a complex lipopolysaccharide (LPS) derived from the outer membrane cell wall of Gram-negative bacteria and is abundant within the gut microbiota, and may play a direct role alongside inhaled allergens in eliciting an inflammatory response in asthma. Endotoxin has immunogenic effects and is sufficiently microscopic to traverse the gut mucosa and enter the systemic circulation to act as a mediator of chronic low-grade inflammation in disease. Whilst the role of endotoxin has been considered in conditions of obesity, cardiovascular disease and T2DM, endotoxin as an inflammatory trigger in asthma is less well understood. This review has sought to examine the current evidence for the role of endotoxin in asthma, and whether the gut microbiota could be a dietary target to improve disease management. This may expand our understanding of endotoxin as a mediator of further low-grade inflammatory diseases, and how endotoxin may represent yet another insult to add to injury.
Asunto(s)
Asma/etiología , Endotoxinas , Inflamación/fisiopatología , Adipoquinas , Asma/fisiopatología , Dieta/efectos adversos , Microbioma Gastrointestinal , Humanos , ObesidadRESUMEN
Brain tumours kill more children and adults under 40 than any other cancer, with approximately half of primary brain tumours being diagnosed as high-grade malignancies known as glioblastomas. Despite de-bulking surgery combined with chemo-/radiotherapy regimens, the mean survival for these patients is only around 15 months, with less than 10% surviving over 5 years. This dismal prognosis highlights the urgent need to develop novel agents to improve the treatment of these tumours. To address this need, we carried out a human kinome siRNA screen to identify potential drug targets that augment the effectiveness of temozolomide (TMZ)-the standard-of-care chemotherapeutic agent used to treat glioblastoma. From this we identified ERK5/MAPK7, which we subsequently validated using a range of siRNA and small molecule inhibitors within a panel of glioma cells. Mechanistically, we find that ERK5 promotes efficient repair of TMZ-induced DNA lesions to confer cell survival and clonogenic capacity. Finally, using several glioblastoma patient cohorts we provide target validation data for ERK5 as a novel drug target, revealing that heightened ERK5 expression at both the mRNA and protein level is associated with increased tumour grade and poorer patient survival. Collectively, these findings provide a foundation to develop clinically effective ERK5 targeting strategies in glioblastomas and establish much-needed enhancement of the therapeutic repertoire used to treat this currently incurable disease.